Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2026)

Adaptive Biotechnologies has reported Current Deferred Revenue for 9 years, with the latest figure at $50.2 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 8.4% year-over-year to $50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.2 million (down 8.4% YoY) and the FY2025 annual result came in at $46.2 million, down 44.3% from the prior year.
• Current Deferred Revenue advanced to $50.2 million in Q1 2026 per ADPT's latest filing, from $46.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $135.2 million in Q3 2022 and troughed at $42.5 million in Q3 2025.
• A 5-year average of $67.4 million and a median of $57.9 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue soared 69.09% in 2022, then tumbled 59.07% in 2023.
• Over 5 years, Current Deferred Revenue stood at $64.1 million in 2022, then jumped by 45.71% to $93.4 million in 2023, then fell by 11.22% to $82.9 million in 2024, then plunged by 44.3% to $46.2 million in 2025, then gained by 8.67% to $50.2 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $50.2 million, $46.2 million, and $42.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.